ClinicalTrials.gg
TerminatedNCT00229749Updated Apr 10, 2008

Study of AVI-4065 in Healthy Volunteers and Chronic Active HCV Patients

A Phase 1/2 interventional study of AVI-4065 Injection in Hepatitis C, sponsored by Sarepta Therapeutics, Inc.. Terminated. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2008-04-10.

Sponsored by Sarepta Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment

How we know

Why this study was terminated
Limited viral load reduction in HCV subjects

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years to 64 Years
Sex
All
01

Study summary

Chronic active hepatitis C viral infections are difficult to treat: current drug therapies can result in severe side effects that some patients will not tolerate. AVI-4065 Injection is a new drug designed to prevent the virus from reproducing in the body. We tested this drug in healthy adult volunteers to optimize the dosing regimen, and are now proceeding in adult patients with chronic active hepatitis C infections. Patients who have the disease and who have had treatment but without success, will be recruited for the study.

The treatment of HCV patients initially consisted of subcutaneous injections given twice a day for 14-days. Treatment arms of 28 days, twice or three-times per day have been added.

Read the detailed description

Hepatitis C virus (HCV) is the most common blood-borne infection in the United States and a worldwide public health problem of epidemic proportions. Benign in the acute phase of infection, HCV infection usually becomes chronic in 70% of those originally infected. Chronic HCV infection leads to inflammation of the liver (hepatitis), cirrhosis, end-stage liver disease, and hepatocellular carcinoma. In the United States alone, there are over 2.7 million individuals with chronic HCV hepatitis. Standard treatment of chronic HCV hepatitis is combination therapy for 24 to 48 weeks with alpha interferon and ribavirin. This combination has limited efficacy, poor tolerability, and significant expense in terms of drug and ancillary laboratory testing. It is well recognized that new treatment options are needed which are more efficacious, potent, less toxic, and less expensive.

AVI BioPharma has pursued discovery of a drug against HCV using proprietary Neugene® or Phosphorodiamidate Morpholino Oligomer (PMO) synthetic chemistry. Neugene (PMO) compounds, as a drug class, are considered safe in humans and do not activate complement, alter clotting times, or bind to α-adrenergic receptors (which can produce hypotension) like the phosphorothioate antisense compounds. One PMO, AVI-4065, has been identified as likely to inhibit all 5 genotypes of HCV based on in vitro and in vivo animal models. There are specific data that confirm that AVI-4065 can inhibit HCV RNA dependent PNA polymerase (RdRp encoded in NS5) and the HCV protease (NS3), in a non-competitive inhibitory fashion. The 50 percent Effective Concentration (EC50) is 308 nM, and the efficacy is nearly 100% at 3 μM. These data suggest that AVI-4065 is capable of inhibiting HCV protein translation in a robust manner at concentrations that should be achievable in patients. In rigorous GLP safety pharmacology and toxicity models in a variety of animal species at dosage levels up to 5 times the maximum anticipated human dosage level, inclusive of non-human primates, AVI-4065 was considered safe, well tolerated and without dose-limiting toxicities. Additionally, AVI-4065 Injection was safe and well-tolerated in the three dose-escalating groups of 31 healthy volunteers (Part I) with no serious adverse events. Adverse events that did occur were few, self-limited and mild to moderate and did not require intervention; this observation held true for the first HCV patients receiving AVI-4065 Injection.

AVI BioPharma's first human use of AVI-4065 Injection involved an open-label, multi-center, exploratory, dose escalating design in healthy adult volunteers. The objective of this part of the study was to assess safety, tolerability and to design a potentially therapeutic dosage regimen. The objective of the second part of the study is to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and signals of HCV virus response in cohorts of HCV patient volunteers that are interferon and ribavirin treatment failures.

The ability of the drug to effect baseline HCV RNA levels over the study duration will be evaluated using a conventional PCR-based assay. If there are promising results from this phase of the clinical trial (viz., a 2 log decrease in HCV RNA levels from baseline within study surveillance), it will provide the rational basis for additional clinical testing of AVI-4065 Injection among HCV patients that are treatment refractory (viz., relapsers and non-responders).

02

Conditions studied

  • Hepatitis C

Browse trials for

Keywords

  • HCV
03

In context

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

This study's planned enrollment of 80 is close to the median of 73 across 1,224 interventional studies indexed under Hepatitis C.

Browse Hepatitis C studies →

Lead sponsor

Sarepta Therapeutics, Inc. is the lead sponsor of 52 studies on the registry; 8 are open to participants now.

Of its 21 completed or terminated interventional studies of FDA-regulated products, 12 (57%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria - Part II: ( Infected Patients)

  • Adult males and females aged 18 to 64 years of age
  • Chronic HCV infection, defined as virological diagnosis of HCV for at least six months with detectable serum HCV-RNA levels >100,000 IU/mL by an HCV-RNA PCR assay on two occasions at least one week apart within 4 weeks prior to study drug administration
  • Signed and dated written form
  • Negative serum ß-HCG (pregnancy) test 24 hours prior to initial dose of AVI-4065 Injection for females of , or and amenorrheic for 2 years, or surgically sterilized for at least one year
  • Willing to abstain from alcohol from the beginning of study entry through Day 28 of the study
  • Willing to participate in all study activities (including the ability to safely self-inject study drug subcutaneously) and all study requirements (including effective ) during study period

Exclusion Criteria - Part II (HCV Patients):

  • Hematology, coagulation, serum chemistry, and urinalysis laboratory test values >2 times or anemia (hemoglobulin \<11 g/dL), leukopenia (total white blood count \<3,000/ µL or total neutrophils \<1,500/ µL) or thrombocytopenia ( \<100,000/ µL)
  • Decompensated or severe liver disease, defined as cirrhotic patients with a score of ≥ 7
  • Encephalopathy or altered mental status of any etiology
  • Any neoplasm, including hepatocellular carcinoma
  • Decompensated renal disease (e.g., serum creatinine >2.5 or on a dialysis program)
  • Positive -1 or HIV-2 serology
  • Positive Surface Antigen (HBsAg) or Hepatitis B Core Antibody (HBcAb) status
  • Participation in any interventional clinical trial within previous 6 months
  • Organ transplant recipient (solid or hematopoietic)
  • Use of interferons and ribavirin or experimental HCV treatment within past 6 months
  • Use of non-steroidal anti-inflammatory agents (e.g., ibuprofen, naproxen or COX-2 inhibitors) that exceeds 2 days per week of the recommended daily dosing or usage that exceeds 5 grams/week.
  • Use of acetaminophen within 15 days of enrollment and throughout Day 28 of the study
  • (BMI) > 35
  • Pregnant or nursing female
  • Active serious or poorly controlled chronic illness
  • History of poor compliance with health and treatment regimens
  • Use of herbal or homeopathic products, illicit drugs, statins, , immunosuppressives, or cytotoxic agents within 90 days of first dose of study drug
  • Use of drugs with potential hepatotoxicity, e.g., oral antifungals or oral glucophage inhibitors
  • Unwilling to participate in any study activity (including to safely self-inject study medication subcutaneously) and complete any study requirement (including effective contraception) during study period and competition of any study visit
  • Investigator opinion of unsuitability
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Interventions

  • DrugAVI-4065 Injection
06

What researchers measure

Primary outcomes

  1. Safety and tolerability

  2. Pharmacokinetics/pharmacodynamics

Secondary outcomes

  1. Response of HCV levels to AVI-4065 Injection, via serum HCV-RNA levels

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2005, a primary completion of Oct 2006 and a completion of Jan 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2005
First posted
Sep 30, 2005
Start
Sep 2005
Primary completionActual
Oct 2006
CompletionActual
Jan 2007
Last update
Apr 10, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00229749
First posted
Sep 30, 2005
Start date
Sep 2005
Primary completion
Oct 2006
Completion
Jan 2007
Last update
Apr 10, 2008

Study contacts

Mark Holodniy, M.D.
principal investigator · Stanford University School of Medicine and Department of Veterans Affairs Public Health Research & Consultation Program at the Veterans Affairs Palo Alto Health Care System
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion